Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Copy number variation analysis of m6 A regulators identified METTL3 as a prognostic and immune-related biomarker in bladder cancer.

Cancer medicine - 1 Nov 2021

Wang Xiaoshuai, Yu Jingwei, Chen Jinbao, Hou Yingdong, Du Zefeng, Huang Haoyang, Tang Siqi, Han Yueyin, Ding Changhai, Xue Zhicheng

Abstract excerpt

PURPOSE: Growing evidence has demonstrated an indispensable role for N6 -methyladenosine (m6 A) in human diseases, but the copy number variations (CNVs) of m6 A regulatory genes in bladder cancer (BLCA) remains largely unknown. METHODS: We investigated the CNVs on all known m6 A regulatory genes using the Cancer Genome Atlas (TCGA) database. The association between CNV events and clinicopathological as well as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Methyltransferases

Share to Mutation

Share to Prognosis

Share to Proportional Hazards Models

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34668652
DOI: 10.1002/cam4.3981
PMCID: PMC8559456

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Copy number variation analysis of m6 A regulators identified METTL3 as a prognostic and immune-related biomarker in bladder cancer.PMID 34668652Read ↗

N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder CancerSemantic proximity Read ↗

Identification and Validation of N6-methyladenosine-related Biomarkers for Bladder Cancer: Implications for ImmunotherapySemantic proximity Read ↗

Gene Alterations of N6-Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study.Semantic proximity Read ↗

The prognostic values and clinical implications of m6A methylation regulators in epithelial ovarian cancerSemantic proximity Read ↗

Significance of KDM6A Mutation in Bladder Cancer Immune EscapeSemantic proximity Read ↗

Significance of KDM6A Mutation in Bladder Cancer Immune EscapeSemantic proximity Read ↗

Identification and Verification of Molecular Subtypes with Enhanced Immune Infiltration Based on m6A Regulators in Cutaneous Melanoma.Semantic proximity Read ↗

Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancerSemantic proximity Read ↗

M5C modulator mediated methylation pattern and TME cell infiltration in bladder cancerSemantic proximity Read ↗

m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancerSemantic proximity Read ↗

Bioinformatic Analysis: Screening and Identification of Differentially Expressed Genes Modified by m6A in Ovarian CancerSemantic proximity Read ↗

Molecular characterization and prognostic relevance of m6A regulators in pancreatic adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.